**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 3928**

**Columns: BRIEF ARTICLES**

**Expression and significance of cyclooxygenase-2 mRNA in benign and malignant ascites**

Lu J *et al.* Detection of cyclooxygenase-2mRNA in ascites

Jing Lu, Xiao-Feng Li, Li-Xia Kong, Lin Ma, Su-Huan Liao, Chang-You Jiang



**Jing Lu, Xiao-Feng Li, Li-Xia Kong, Lin Ma, Su-Huan Liao,** the Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai 519000, Guangdong Province, China

**Chang-You Jiang,** Health Bureau of Jinwan District, Zhuhai 519000, Guangdong Province, China

**Author contributions:** Lu J was responsible for performing the research and for drafting the article; Li XF designed the research and was responsible for final approval of the manuscript; Kong LX and Ma L provided critical revision of the manuscript; LiaoSHand Jiang CY analyzed the data and interpreted the results.

**Supported by** Foundation of Science and Technology Plan Project in Zhuhai, No. PC20061084

**Correspondence to: Dr. Lin Ma,** Department of the Fifth Affiliated Hospital of Sun Yat-Sen University, 52nd Meihua Road West, Zhuhai 519000, Guangdong Province, China. linma1227@hotmail.com

**Telephone:** +86-756-2528845  **Fax:** +86-756-2528845

**Received:** June 2, 2013  **Revised:** August 8, 2013

**Accepted:** September 3, 2013

**Published online:**

**Abstract**

**AIM:** To investigate the mRNA expression of cyclooxygensae-2 (COX-2) in benign and malignant ascites, and to explore the difference in COX-2 mRNA expression among different diseases.

**METHODS:** Total of 36 samples were collected from the Fifth Affiliated Hospital of Sun Yat-Sen University and divided into 2 experimental groups: benign ascites(*n* = 21) and malignant ascites(*n* = 15). Benign ascites including cirrhotic ascites(*n* = 10), tuberculous ascites(*n* = 5). Malignant ascites including oophoroma(*n* = 7), cancer of colon(*n* = 5), cancer of the liver(*n* = 6), gastric cancer(*n* = 2), bladder carcinoma(*n* = 1). The mRNA expression of COX-2 in ascites was examined with reverse transcriptase polymerase chain reaction (RT-PCR) technology, and then the positive rate of COX-2 mRNA was compared between different diseases.

**RESULTS:** The positive rate of COX-2 mRNA in malignant ascites was 42.9% (9/21), which was significantly higher than that of benign ascites, 6.7% (1/15), there was significant difference between these two groups (*χ*2 = 4.051, *P* = 0.044). The proportion of the positive rate in the malignant ascites was: ovarian cancers 57.1% (4/7), colon cancer 40.0% (2/5), liver cancer 33.3% (2/6), gastric cancer 50.0% (1/2), bladder cancer 0.00% (0/1). However, there was no significant difference in COX-2 mRNA expression among various tumors with malignant ascites (*χ*2 = 1.614, *P* = 0.806). Among the benign ascites, COX-2 mRNA levels between the tuberculous ascites (0/5) and cirrhotic ascites (1/10) were different, but there was no significant difference between them (*P* = 1.000).

**CONCLUSION**: COX-2 mRNA, detected by RT-PCR, was useful in the differential diagnosis of benign and malignant ascites, which also has potential value in the clinical diagnosis of tumors.

© 2013 Baishideng. All rights reserved.

**Key words:** Ascites; COX-2 mRNA; Reverse transcriptase polymerase chain reaction; Malignant tumor

**Core tip:** Ascites is a common symptom caused by a variety of diseases, the differential diagnosis between benign ascites and malignant ascites is one of the most important clinical problems. Commonly, cytology examination and ascites tumor markers can provide important evidence, but the sensitivity and specificity of these examinations are far from satisfactory. Our study aimed to explore the difference in cyclooxygensae-2 (COX-2) mRNA expression among different diseases. Our research suggests COX-2mRNA can be detected by reverse transcriptase polymerase chain reaction, but there are no significant differences in the expression of COX-2 mRNA among various disease types with benign or malignant ascites.

Lu J, Li XF, Kong LX, Ma L, Liao SH, Jiang CY. Expression and significance of cyclooxygenase-2 mRNA in benign and malignant ascites.

**Available from:**

**DOI:**

**INTRODUCTION**

Ascites is a gastroenterological term for an accumulation of fluid in the peritoneal cavity, which might result from cirrhosis, tuberculous peritonitis or a malignant tumor.

The detection of exfoliated ascites cells is usually used to identify these diseases in the clinic, but there is no economic, practical, or effective index with high specificity. Therefore, it is still a major problem for clinical diagnosis and treatment to discriminate benign and malignant ascites[1,2].

In recent years, cyclooxygensae-2 (COX-2) has been extensively studied as an inducible expression protein, and has been detected in various tumor tissues in epidemiology and cytology research[3,4],such as pancreatic cancer, colorectal carcinoma, non-small lung cancer and so on. Lots of research has found that COX-2 expression is unregulated in precancerous lesions and preinvasive carcinoma and positively correlates with tumor invasion and lymphatic metastasis[5,6]. Therefore, increasing expression of COX-2 might occur in the early stages of the tumor and the detection of COX-2 level is helpful for early diagnosis.

However, there are only few studies regarding COX-2 expression in benign and malignant ascites at home and abroad. We employed reverse transcriptase polymerase chain reaction (RT-PCR) technology to detect the expression level of COX-2 in benign and malignant ascites, and analyzed the difference in mRNA expression of COX-2 among different diseases.

**MATERIALS AND METHODS**

***Subjects***

A total of 36 patients with ascites who underwent abdominocentesis at the Fifth Affiliated Hospital of Sun Yat-sen University between August 2011 and March 2012 were selected. The subjects were divided into benign and malignant groups according to medical history, physical examination, B ultrasound, computed tomography (CT), pathology and the presence of exfoliated tumor cells. There were 15 cases of benign ascites, including nine males and six females, aged 43-75 years with an average age of 62.5 ± 1.8 years; the patients consisted of 10 cases of cirrhosis and five cases of tuberculous peritonitis according to disease type. There were 21 cases of malignant ascites, including 11 males and 10 females, aged 41-79 years with an average age of 58 ± 2.3 years; the patients consisted of seven cases of ovarian cancer, five cases of colon cancer, six cases of liver cancer, two cases of gastric cancer and one case of bladder cancer according to disease type.

The samples were centrifuged at 3000 r/min for 15 min immediately after collection from the patients, and the supernatant was removed. The pellet was stored in -80°C refrigerator for total RNA extraction.

The sample collection was approved by the ethics committee of Zhuhai and the patients provided written informed consent.

***RT-PCR***

**Primer design:** The gene sequences of the primers were designed with Primer Premier 5.0 software according to the literature[5,6] and mRNA sequences for human COX-2 reported by NCBI; GAPDH was selected as the positive control primer for RT-PCR and synthesized by the Shanghai ShengGong Biological Engineering Co., Ltd. (Table 1).

**Total RNA extraction:** Total RNA was extracted from benign and malignant ascites with RNA extraction reagent (Trizol, Invitrogen, United States), and its content and purity were measured by ultraviolet spectrophotometry [1.9 < D(260)/D(280) < 2.1].

**Synthesis of cDNA by reverse transcription:** Reverse transcription was performed to synthesize cDNA with the AMV Reverse Transcriptase Kit, in which AMV was reverse transcriptase and olig(dt)18 was the primer. The RT-PCR reaction mixture was 10 μL, containing 1 μL of extracted total RNA, 2 μL of MgCl2, 1 μL of 10×RNA PCR Buffer, 3.75 μL of RNase Free dH2O, 1 μL of dNTP Mixture, 0.25 μL of RNase Inhibitor, 0.5 μL of AMV Reverse Transcriptase and 0.5 μL of Oligo dT-Adaptor Primer. The reaction conditions were set tot 30°C for 10 min, 50°C for 30 min, 99°C for 5 min and 5°C for 5 min.

**PCR amplification:** After reverse transcription, cDNA was used as the template in PCR amplification with primers for COX-2 and GAPDH; a negative control was established. The PCR reaction mixture was 50 μL, including 3 μL of MgCl₂, 4 μL of 10 × LA PCR Buffer II (Mg²+Free), 31.75 μL of sterilized distilled water, 0.25 μL of TaKaRa LA Taq and 1 μL of the COX-2 or GAPDH primers. The PCR cycle consisted of the following steps: denaturing at 94°C for 30 s, annealing at 60°C for 30 s and elongation at 72°C for 1.5 min, which was repeated for 30 cycles. Amplification products were utilized for electrophoresis in a 1.5% agarose gel, and were observed and photographed under ultraviolet light.

***Statistical analysis***

Statistical analysis was processed with SPSS 13.0 software and qualitative data was described by frequency and rate; the comparison between groups of qualitative data utilized the Chi-square test with Yates' continuity correction and Fisher’s exact probability test; *P* < 0.05 was considered significant.

**RESULTS**

***mRNA expression of COX-2 in benign and malignant ascites***

The positive rate of COX-2 mRNA in malignant ascites was 42.9% (9/21), which was significantly higher than that of benign ascites, 6.7% (1/15), but there was significant difference between these two groups (*χ*2= 4.051, *P* = 0.044) (Table 2).

***mRNA expression of COX-2 among different disease types in benign group***

Among the benign ascites, COX-2 mRNA levels between the tuberculous ascites (0/5) and cirrhotic ascites (1/10) were different, but there was no significant difference between them (*P* = 1.000) (Table 3).

***mRNA expression of COX-2 among different disease types in the malignant group***

The proportion of the positive rate in the malignant ascites was: ovarian cancers 57.1% (4/7), colon cancer 40.0% (2/5), liver cancer 33.3% (2/6), gastric cancer 50.0% (1/2), bladder cancer 0.00% (0/1). However, There was no significant difference in COX-2 mRNA expression among various tumors with malignant ascites (*χ*2 = 1.614, *P* = 0.806; *P* > 0.05) (Table 4).

**DISCUSSION**

COX, or prostaglandin-endoperoxide synthase (PGH), is a major rate-limiting enzyme in the synthesis of prostaglandin, which is able to metabolize arachidonic acid into prostaglandin products[7-9]. COX-2, an inducible protein expression, is absent in normal cells and tissue, but is rapidly synthesized and expressed under pathological conditions or after stimulation (such as inflammation, hypoxia, laser radiation, ultraviolet radiation, *etc.*). COX-2 is involved in a variety of pathophysiological processes, such as the occurrence and development of inflammation and cancer, *etc*[10]. At present, mRNA expression of COX-2 in various tumor tissues has been extensively investigated; more and more research has demonstrated that COX-2 expression is unregulated in precancerous lesions and preinvasive carcinoma and positively correlates with tumor invasion and lymphatic metastasis[11-14]. Therefore, increasing expression of COX-2 might occur in the early stages of the tumor and the detection of COX-2 level is helpful for early diagnosis[15,16].

Ascites is a common symptom of many diseases and the identification of benign and malignant ascites is a common and important clinical problem. So far, smear tests of exfoliated cells from ascites and the detection of tumor markers, such as CA-125, CA19-9 and AFP, have been employed to identify ascites induced by malignant tumors, but these indices are far from satisfying in terms of sensitivity and specificity, so it is important to search for a new indicator of benign and malignant ascites[17-21] Since COX-2 has a close relationship with tumors, its expression in malignant ascites has become an issue that is worth exploring.

Our research employed RT-PCR to assess the mRNA expression of COX-2 in 21 cases of malignant ascites. The positive rate of COX-2 mRNA was 42.9% (9/21), which was significantly higher than in benign ascites, 6.7% (1/15) (*P* < 0.05). This result indicated that the measurement of COX-2 mRNA facilitates the identification of benign and malignant ascites and has potential value for clinical diagnosis and screening of tumors. In previous studies on COX-2, its expression was usually detected in malignant tumor tissue[22-24], but our experiment used ascites as the samples. These were convenient to collect from patients with less pain and easy for clinical application due to the high practical value. In addition, COX-2 is absent in normal cells and tissues as an inducible expression protein with specificity, so is a potential indicator for the identification of benign and malignant ascites, and an effective supplement to common indices, such as CA125, CA19-9 and AFP.

There were no significant differences in the expression of COX-2 mRNA among various disease types with benign or malignant ascites (*P* > 0.05), which was probably associated with the small number of samples and requires further confirmation. We employed one step RT-PCR, which was easy to perform, required little contact with experimental samples and avoided unnecessary contamination, and also facilitated further research and the development of clinical detection kits.

In conclusion, identification of benign and malignant ascites is of importance for the clinical diagnosis of diseases and is helpful for designing a treatment plan. We hope our study can provide a new direction to explore this field in the future.

**COMMENTS**

***Background***

In recent years, cyclooxygensae-2 (COX-2) has been extensively studied as an inducible expression protein, and has been detected in various tumor tissues in epidemiology and cytology research. Therefore, increasing expression of COX-2 might occur in the early stages of the tumor and the detection of COX-2 level is helpful for early diagnosis.

***Research frontiers***

At present, mRNA expression of COX-2 in various tumor tissues has been extensively investigated; more and more research has demonstrated that COX-2 expression is unregulated in precancerous lesions and preinvasive carcinoma and positively correlates with tumor invasion and lymphatic metastasis. Therefore, increasing expression of COX-2 might occur in the early stages of the tumor and the detection of COX-2 level is helpful for early diagnosis.

***Innovations and breakthroughs***

This study employed RT-PCR to assess the mRNA expression of COX-2 in 21 cases of malignant ascites. The positive rate of COX-2 mRNA was 42.9% (9/21), which was significantly higher than in benign ascites, 6.7% (1/15) (*P* < 0.05). This result indicated that the measurement of COX-2 mRNA facilitates the identification of benign and malignant ascites and has potential value for clinical diagnosis and screening of tumors.

***Applications***

Identification of benign and malignant ascites is of importance for the clinical diagnosis of diseases and is helpful for designing a treatment plan. The study can provide a new direction to explore this field in the future.

***Peer review***

This is an interesting manuscript about mRNA expression of COX-2 in benign and malignant ascites. The authors made a good research on this topic. Differences in COX-2 mRNA expression among different diseases were explored. The data is well present and discussed.

**REFERENCES**

1 **Metzgeroth G**, Kuhn C, Schultheis B, Hehlmann R, Hastka J. Diagnostic accuracy of cytology and immunocytology in carcinomatous effusions. *Cytopathology* 2008; **19**: 205-211 [PMID: 17573908 DOI: 10.1111/j.1365-2303.2007.00468.x]

2 **Gu H,** Deng XY, Yan L, Zhang GY. The diagnosis potential of the ratio for the differentiation between benign and malignant ascites by the combined measurement of ascites and serum tumor markers as well as the F/S ratio. *Zhongguo Xiandai yixue Zahi* 2011; **14**: 1595-1599

3 **Hill R**, Li Y, Tran LM, Dry S, Calvopina JH, Garcia A, Kim C, Wang Y, Donahue TR, Herschman HR, Wu H. Cell intrinsic role of COX-2 in pancreatic cancer development. *Mol Cancer Ther* 2012; **11**: 2127-2137 [PMID: 22784710 DOI: 10.1158/1535-7163.MCT-12-0342]

4 **Jiang H**, Wang J, Zhao W. Cox-2 in non-small cell lung cancer: a meta-analysis. *Clin Chim Acta* 2013; **419**: 26-32 [PMID: 23384501 DOI: 10.1016/j.cca.2013.01.012]

5 **Lurje G**, Vallbohmer D, Collet PH, Xi H, Baldus SE, Brabender J, Metzger R, Heitmann M, Neiss S, Drebber U, Holscher AH, Schneider PM. COX-2 mRNA expression is significantly increased in acid-exposed compared to nonexposed squamous epithelium in gastroesophageal reflux disease. *J Gastrointest Surg* 2007; **11**: 1105-1111 [PMID: 17619937 DOI: 10.1007/s11605-007-0210-3]

6 **Strazisar M**, Mlakar V, Glavac D. The expression of COX-2, hTERT, MDM2, LATS2 and S100A2 in different types of non-small cell lung cancer (NSCLC). *Cell Mol Biol Lett* 2009; **14**: 442-456 [PMID: 19238334 DOI: 10.2478/s11658-009-0011-7]

7 **Li Q**, Liu N, Shen B, Zhou L, Wang Y, Wang Y, Sun J, Fan Z, Liu RH. Helicobacter pylori enhances cyclooxygenase 2 expression via p38MAPK/ATF-2 signaling pathway in MKN45 cells. *Cancer Lett* 2009; **278**: 97-103 [PMID: 19201083 DOI: 10.1016/j.canlet.2008.12.032]

8 **Boutaud O,** Oates JA. Study of inhibitors of the PGH synthases for which potency is regulated by the redox state of the enzymes. *Methods Mol Biol* 2010; **644**: 67-90 [PMID: 20645166]

9 **Patrono C.** The PGH-synthase system and isozyme-selective inhibition. *J Cardiovasc Pharmacol* 2006; **47**: 1-6 [PMID: 16785823 DOI: 10.1097/00005344-200605001-00002]

10 **Zhang JB,** Gu XY, Zhu XH, He S, ZhOu JY, Yu L. The clinical significance of PTEN,Survivin and COX-2 protein expressions in breast carcinoma tissues. *Zhonghua Zhongliu Fangzhi Zazhi* 2010; **17**, 1927-1930

11 **Zou TN,** Hu FD,Chen Y,Tang YY. The expressions and correlation of COX-2 and ERmRNA in breast carcinoma tissues and their relevant research. *Zhonghua Zhongliu Fangzhi Zazhi* 2008; **15**: 758-761

12 **Xia W**, Zhao T, Lv J, Xu S, Shi J, Wang S, Han X, Sun Y. Celecoxib enhanced the sensitivity of cancer cells to anticancer drugs by inhibition of the expression of P-glycoprotein through a COX-2-independent manner. *J Cell Biochem* 2009; **108**: 181-194 [PMID: 19562670 DOI: 10.1002/jcb.22239]

13 **Wu ZL,** Sun GP, Wu Q, Fan LL, Fu WZ. Expression and its correlation of Cox-2 and Her-2/neu in gastric carcinoma tissues. *Anhui Yiyao* 2010; **14**: 1171-1173

14 **Salimi M**, Esfahani M, Habibzadeh N, Aslani HR, Amanzadeh A, Esfandiary M, Sedaghati B, Bidgoli SA, Ghahremani MH. Change in nicotine-induced VEGF, PGE2 AND COX-2 expression following COX inhibition in human oral squamous cancer. *J Environ Pathol Toxicol Oncol* 2012; **31**: 349-356 [PMID: 23394447 DOI: org/10.1615/JEnvironPatholToxicolOncol.2013005365]

15 **Hua TB,** Meng XY, Wang GY, ZhangQ, Ren J, Jiu J, Chen G. Detection of COX-2, MMP-9, VEGF and RET in thyroid tissues and significances in primary diagnosis of papillary thyroid carcinoma. *Jilin Daxue Xuebao* 2011; **37**: 712-717

16 **Huang YQ,** Song YF, Yi JG. The expression and clinical significance of cyclooxygenase-2 and vascular endothelial growth factor-C in oral squamous cell carcinoma. *Linchuang Kouqiang Yixue Zazhi* 2011; **27**: 337-339

17 **Chen BP,** Ling SJ. Value of Combined Detection of CEA, CA 19-9 and 125 in Differential Diagnosis Between Benign and Malignant Ascites. *Linchuang Xiaohuabing Zazhi* 2010; **22:** 208-210

18 **Passebosc-Faure K**, Li G, Lambert C, Cottier M, Gentil-Perret A, Fournel P, Pérol M, Genin C. Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions. *Clin Cancer Res* 2005; **11**: 6862-6867 [PMID: 16203775 DOI: 10.1158/1078-0432.CCR-05-0043]

19 **Yu JR,** Wu YJ, Fu PF, Lv KZ, Gao Y, Xie HY, Zheng SS. The clinical significance of carcinoembryonic antigen mRNA detection in the peritoneal washes of stomach neoplasms patients. *Zhonghua Putongwaike Zazhi* 2004; **19**: 771

20 **Lin YY**, Li JJ, Chang CH, Lu YC, Hwang JJ, Tseng YL, Lin WJ, Ting G, Wang HE. Evaluation of pharmacokinetics of 111In-labeled VNB-PEGylated liposomes after intraperitoneal and intravenous administration in a tumor/ascites mouse model. *Cancer Biother Radiopharm* 2009; **24**: 453-460 [PMID: 19694580 DOI: 10.1089/cbr.2008.0572]

21 **Horton HM**, Dorigo O, Hernandez P, Anderson D, Berek JS, Parker SE. IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile. *J Immunol* 1999; **163**: 6378-6385 [PMID: 10586027]

22 **Zhang Q,** Mu YS, Wang ZF, Wang XL, Gao F. Correlation of cyclooxygenase-2 mRNA expression with occurrence and development of esophageal carcinoma. *Zhonghua Zhongliu Fangzhi Zazhi* 2008; **15**: 178-180

23 **Shao N**, Feng N, Wang Y, Mi Y, Li T, Hua L. Systematic review and meta-analysis of COX-2 expression and polymorphisms in prostate cancer. *Mol Biol Rep* 2012; **39**: 10997-11004 [PMID: 23053989 DOI: 10.1007/s11033-012-2001-5]

24 **Dixon DA**, Blanco FF, Bruno A, Patrignani P. Mechanistic aspects of COX-2 expression in colorectal neoplasia. *Recent Results Cancer Res* 2013; **191**: 7-37 [PMID: 22893198 DOI: 10.1007/978-3-642-30331-9\_2]

**P-Reviewers** Ehrenpreis ED, Kalambokis G **S-Editor** Wang JL

**L-Editor E-Editor**

**Table 1 Primer sequences of cyclooxygensae-2 and** **glyceraldehyde-3-phosphate dehydrogenase genes**

|  |  |  |  |
| --- | --- | --- | --- |
| **Primer** |  | **Primer sequence** | **Product size** |
| COX-2  GAPDH | Forward primer  Reverse primer  Forward primer  Reverse primer | 5’-CTTGGGTGTCAAAGGTAA-3’  5’-AGGGACTTGAGGAGGGTA-3’  5’-GTGGGGCGCCAGGCACCA-3’  5’-CTCCTATGTCACGCACATTC-3’ | 581bp  146bp |

COX-2: Cyclooxygensae-2; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Table 2 mRNA expression of cyclooxygensae-2 in benign and malignant ascites *n* (%)** | | | | |
| **Group** | **COX-2 mRNA expression** | | ***χ2*** | ***P*** |
| **Positive** | **Negative** |
| Benign ascites | 1(6.7) | 14(93.3) | 4.051 | 0.044 |
| Malignant ascites | 9(42.9) | 12(57.1) |
| The comparison between groups utilized Yates' continuity correction; *P* < 0.05 was considered as significance. COX-2: Cyclooxygensae-2. | | | | |

**Table 3 mRNA expression of cyclooxygensae-2 among different disease types in benign group *n* (%)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Group** | **COX-2 mRNA expression** | | ***P*** |
| **Positive** | **Negative** |
| Cirrhosis with ascites | 1(6.7) | 9(60) | 1.000 |
| tuberculous ascites | 0(0.0) | 5(33.3) |
| The comparison between groups utilized Fisher’s exact probability test; *P* > 0.05 was considered as no significance. COX-2: Cyclooxygensae-2.  **Table 4 mRNA expression of cyclooxygensae-2 among different disease types in malignant group (Cases) *n* (%)**   |  |  |  |  |  | | --- | --- | --- | --- | --- | | **Group** | **COX-2 mRNA expression** | | ***χ2*** | ***P*** | | **Positive** | **Negative** | | Ovarian cancer | 4(19.0) | 3(14.3) | 1.614 | 0.806 | | Colon cancer | 2(9.5) | 3(14.3) | | Liver cancer | 2(9.5) | 4(19.0) | | Gastric cancer | 1(4.8) | 1(4.8) | | Bladder cancer | 0(0.0) | 1(4.8) | | | | |

The comparison between groups utilized *χ2* test, *P* > 0.05 was considered as no significance. COX-2: Cyclooxygensae-2.